BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34608266)

  • 1. RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA.
    Block CJ; Mitchell AV; Wu L; Glassbrook J; Craig D; Chen W; Dyson G; DeGracia D; Polin L; Ratnam M; Gibson H; Wu G
    Oncogene; 2021 Nov; 40(46):6430-6442. PubMed ID: 34608266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DCAF13 promotes triple-negative breast cancer metastasis by mediating DTX3 mRNA degradation.
    Liu J; Li H; Mao A; Lu J; Liu W; Qie J; Pan G
    Cell Cycle; 2020 Dec; 19(24):3622-3631. PubMed ID: 33300431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer.
    Lv ZD; Kong B; Liu XP; Jin LY; Dong Q; Li FN; Wang HB
    J Cell Mol Med; 2016 May; 20(5):864-73. PubMed ID: 26820102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial-mesenchymal transition in triple-negative breast cancer.
    Lv ZD; Yang ZC; Liu XP; Jin LY; Dong Q; Qu HL; Li FN; Kong B; Sun J; Zhao JJ; Wang HB
    J Cell Mol Med; 2016 Sep; 20(9):1640-50. PubMed ID: 27027510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
    Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
    Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA-binding protein RBMS3 is expressed in activated hepatic stellate cells and liver fibrosis and increases expression of transcription factor Prx1.
    Fritz D; Stefanovic B
    J Mol Biol; 2007 Aug; 371(3):585-95. PubMed ID: 17586524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RNA binding protein RBMS3 inhibits the metastasis of breast cancer by regulating Twist1 expression.
    Zhu L; Xi PW; Li XX; Sun X; Zhou WB; Xia TS; Shi L; Hu Y; Ding Q; Wei JF
    J Exp Clin Cancer Res; 2019 Feb; 38(1):105. PubMed ID: 30819235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB.
    Okita Y; Kimura M; Xie R; Chen C; Shen LT; Kojima Y; Suzuki H; Muratani M; Saitoh M; Semba K; Heldin CH; Kato M
    Sci Signal; 2017 Apr; 10(474):. PubMed ID: 28400538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.
    Zhang J; Shao X; Sun H; Liu K; Ding Z; Chen J; Fang L; Su W; Hong Y; Li H; Li H
    Oncotarget; 2016 Sep; 7(38):61036-61053. PubMed ID: 27506933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
    Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
    J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
    Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
    Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down regulation of RNA binding motif, single-stranded interacting protein 3, along with up regulation of nuclear HIF1A correlates with poor prognosis in patients with gastric cancer.
    Wu Y; Yun D; Zhao Y; Wang Y; Sun R; Yan Q; Zhang S; Lu M; Zhang Z; Lu D; Li Y
    Oncotarget; 2017 Jan; 8(1):1262-1277. PubMed ID: 27902480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
    Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
    Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-6838-5p suppresses cell metastasis and the EMT process in triple-negative breast cancer by targeting WNT3A to inhibit the Wnt pathway.
    Liu G; Wang P; Zhang H
    J Gene Med; 2019 Dec; 21(12):e3129. PubMed ID: 31693779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RBMS3 Inhibits the Proliferation and Metastasis of Breast Cancer Cells.
    Yang Y; Quan L; Ling Y
    Oncol Res; 2018 Jan; 26(1):9-15. PubMed ID: 28409548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
    Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
    Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
    Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer.
    Lai YW; Hsu WJ; Lee WY; Chen CH; Tsai YH; Dai JZ; Yang CC; Lin CW
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
    Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.